• +1-646-491-9876
    • +91-20-67278686

    Search

    Histone Lysine N Methyltransferase EZH2 Pipeline Review H1 2017

    Histone Lysine N Methyltransferase EZH2 Pipeline Review H1 2017

    • Report Code ID: RW0001851082
    • Category Life Sciences
    • No. of Pages 71
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Pipeline Review, H1 2017

    Summary

    Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) pipeline Target constitutes close to 15 molecules. Out of which approximately 15 molecules are developed by Companies. The latest report Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H1 2017, outlays comprehensive information on the Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type.

    Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-methyltransferase enzyme encoded by EZH2 gene. EZH2 methylates non-histone proteins such as the transcription factor GATA4 and the nuclear receptor RORA. It regulates the circadian clock via histone methylation at the promoter of the circadian genes. It is essential for the CRY1/2-mediated repression of the transcriptional activation of PER1/2 by the CLOCK-ARNTL/BMAL1 heterodimer, involved in the di and trimethylation of Lys-27 of histone H3 on PER1/2 promoters which is necessary for the CRY1/2 proteins to inhibit transcription. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 5 and 6 respectively. Report covers products from therapy areas Oncology and Undisclosed which include indications Lymphoma, Diffuse Large B-Cell Lymphoma, Multiple Myeloma (Kahler Disease) , Non-Hodgkin Lymphoma, Follicular Lymphoma, Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) , Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) , Breast Cancer, Chondrosarcoma, Epithelial Tumor, Hematological Tumor, Lung Cancer, Malignant Mesothelioma, Mantle Cell Lymphoma, Melanoma, Metastatic Liver Cancer, Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) , Primary Mediastinal B-Cell Lymphoma, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rhabdomyosarcoma, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Synovial Sarcoma and T-Cell Leukemia.

    Furthermore, this report also reviews key players involved in Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43)
    - The report reviews Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Overview
    Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Companies Involved in Therapeutics Development
    Daiichi Sankyo Company Ltd
    Domainex Ltd
    EpiZyme Inc
    GlaxoSmithKline Plc
    Kainos Medicine Inc
    Pfizer Inc
    Transgene Biotek Ltd
    UNC Health Care
    Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Drug Profiles
    CPI-1205 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CPI-169 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DS-3201 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    EBI-2554 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GSK-2816126 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GSK-343 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    JQEZ-5 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KM-301 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ORS-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit EZH2 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit EZH2 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit EZH2 for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit EZH2-EED for Oncology - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tazemetostat - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TBL-0404 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Dormant Products
    Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Discontinued Products
    Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Product Development Milestones
    Featured News & Press Releases
    May 18, 2017: Epizyme Announces Path Toward Tazemetostat Registration in Epithelioid Sarcoma and Reports New Clinical Data to be Presented at ASCO
    Apr 25, 2017: Epizyme Announces Tazemetostat Fast Track Designation for Follicular Lymphoma and Plenary Session on Phase 2 NHL Data at ICML
    Apr 20, 2017: Epizyme Announces Date of First Quarter 2017 Financial Results and Tazemetostat Data Presentations at ASCO
    Nov 28, 2016: Epizyme Announces Fast Track Designation for Tazemetostat in DLBCL and Provides Solid Tumor Program Update
    Aug 11, 2016: Epizyme Doses First Patient in Global Phase 2 Study Evaluating Tazemetostat in Mesothelioma
    Jun 19, 2016: Epizyme Reports Early Data from Global Phase 2 Trial of Tazemetostat in Non-Hodgkin Lymphoma at ASH Lymphoma Biology Meeting
    May 12, 2016: Epizyme to Present Data From the Tazemetostat Non-Hodgkin Lymphoma Program at American Society for Hematology Meeting on Lymphoma Biology
    May 04, 2016: Epizyme Announces FDA Acceptance of Investigational New Drug Application for Tazemetostat in Mesothelioma
    May 03, 2016: New investigational compound shows promise against melanoma, lymphoma
    Apr 18, 2016: Epizyme Presents Data from Tazemetostat Clinical Pharmacology Studies at American Association for Cancer Research Annual Meeting 2016
    Mar 17, 2016: Epizyme to Present New Data in Support of Tazemetostat Clinical Development Program
    Mar 09, 2016: Epizyme Unveils Corporate Strategy to Guide Efforts over Next Five Years
    Feb 08, 2016: Epizyme Announces Tazemetostat Granted Orphan Drug Designation for Malignant Rhabdoid Tumors by U.S. FDA
    Dec 30, 2015: Epizyme Announces First Patient Dosed in Global Clinical Program Evaluating Tazemetostat in Genetically Defined Solid Tumors
    Dec 28, 2015: Epizyme Announces FDA Acceptance of Investigational New Drug Application for Tazemetostat in Diffuse Large B-cell Lymphoma
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indications, H1 2017
    Number of Products under Development by Indications, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Companies, H1 2017 (Contd..2) , H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Daiichi Sankyo Company Ltd, H1 2017
    Pipeline by Domainex Ltd, H1 2017
    Pipeline by EpiZyme Inc, H1 2017
    Pipeline by GlaxoSmithKline Plc, H1 2017
    Pipeline by Kainos Medicine Inc, H1 2017
    Pipeline by Pfizer Inc, H1 2017
    Pipeline by Transgene Biotek Ltd, H1 2017
    Pipeline by UNC Health Care, H1 2017
    Dormant Projects, H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Top 10 Indications, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Daiichi Sankyo Company Ltd
    Domainex Ltd
    EpiZyme Inc
    GlaxoSmithKline Plc
    Kainos Medicine Inc
    Pfizer Inc
    Transgene Biotek Ltd
    UNC Health Care

    Request for Sample

    Report Url https://www.reportsweb.com//histone-lysine-n-methyltransferase-ezh2-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//histone-lysine-n-methyltransferase-ezh2-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//histone-lysine-n-methyltransferase-ezh2-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments